Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence Driven Adjusted OCT-Based Classification System for Diabetic Macular Edema (AIDME).

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Impact of AI-enhanced three-dimensional OCT scans on disease activity assessment in patients with nAMD: the RAZORBILL study.

The British journal of ophthalmology·2026
Same author

Functional and Anatomic Outcomes in Eyes With Primary Epiretinal Membranes After Surgical Removal: 5-Year Results of the Pan American Collaborative Retina Study Group.

Journal of vitreoretinal diseases·2026
Same author

Phenotyping of Patients with Age-Related Macular Degeneration Using Artificial Intelligence-Driven Biomarker Patterns in OCT.

Ophthalmology science·2026
Same author

Geographic Atrophy Structure-Function Relationships Based on Loss of OCT Outer Retinal Bands and Fundus Autofluorescence.

Ophthalmology science·2026
Same author

Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project.

The British journal of ophthalmology·2026

Related Experiment Video

Updated: Jul 9, 2025

Lensless On-chip Imaging of Cells Provides a New Tool for High-throughput Cell-Biology and Medical Diagnostics
08:19

Lensless On-chip Imaging of Cells Provides a New Tool for High-throughput Cell-Biology and Medical Diagnostics

Published on: December 14, 2009

12.0K

Development of LuxIA, a Cloud-Based AI Diabetic Retinopathy Screening Tool Using a Single Color Fundus Image.

Joseph P M Blair1, Jose Natan Rodriguez2, Romina M Lasagni Vitar1

  • 1RetinAI Medical AG, Bern, Switzerland.

Translational Vision Science & Technology
|November 30, 2023
PubMed
Summary

An AI tool, LuxIA, effectively screens for diabetic retinopathy (DR) using single fundus images. This cloud-based system offers accessible, expert-level DR detection, improving early diagnosis for diabetic patients.

More Related Videos

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.4K
Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases
07:22

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

11.5K

Related Experiment Videos

Last Updated: Jul 9, 2025

Lensless On-chip Imaging of Cells Provides a New Tool for High-throughput Cell-Biology and Medical Diagnostics
08:19

Lensless On-chip Imaging of Cells Provides a New Tool for High-throughput Cell-Biology and Medical Diagnostics

Published on: December 14, 2009

12.0K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.4K
Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases
07:22

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

11.5K

Area of Science:

  • Ophthalmology
  • Medical Imaging
  • Artificial Intelligence

Background:

  • Diabetic retinopathy (DR) is a primary cause of vision loss in adults.
  • Automated screening tools can enhance early DR detection cost-effectively.

Purpose of the Study:

  • To develop and assess a cloud-based AI tool, LuxIA, for detecting diabetic retinopathy from single fundus images.
  • To evaluate the performance and clinical integration of the LuxIA algorithm.

Main Methods:

  • A deep-learning algorithm, LuxIA, was trained on expert-graded fundus images.
  • The algorithm was deployed on the Discovery cloud platform for evaluation.
  • Performance metrics (sensitivity, specificity, accuracy) were assessed on multiple datasets, alongside a usability test.

Main Results:

  • LuxIA demonstrated high performance across three independent datasets, with mean sensitivities ranging from 0.901 to 0.995 and specificities from 0.821 to 0.955.
  • The usability test confirmed seamless integration of LuxIA into the Discovery clinical platform.

Conclusions:

  • The LuxIA algorithm achieves expert-level performance in detecting diabetic retinopathy.
  • The cloud-based Discovery platform facilitates wider access to advanced DR screening tools for diabetic patients.